Recital 12, Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…

In forcesince 29 Mar 2006

The planning of studies and of the submission of an application for a marketing authorisation occurs at an early stage in the development of medicinal products. Such planning will critically depend on whether a conditional marketing authorisation is a possibility. For this reason it is necessary to provide a mechanism for the Agency to give companies advice on whether a medicinal product falls within the scope of this Regulation. Such advice should be an additional service to the existing scientific advice provided by the Agency.